Back

IL-1B-mediated inflammatory signaling drives ineffective erythropoiesis in early-stage myelodysplastic syndromes

Adema, V.; Ganan-Gomez, I.; Ma, F.; Rodriguez-Sevilla, J. J.; Chien, K.; Yang, H.; Thongon, N.; Kanagal-Shamanna, R.; Loghavi, S.; Montalban-Bravo, G.; Hammond, D.; Gu, Y.; Tan, R.; Tan, L.; Lorenzi, P.; Al-Atrash, G.; Clise-Dwyer, K.; Bejar, R.; Pellegrini, M.; Garcia-Manero, G.; Colla, S.

2023-09-30 cancer biology
10.1101/2023.09.28.560018 bioRxiv
Show abstract

Myelodysplastic syndromes (MDS) are a group of incurable hematopoietic stem cell (HSC) neoplasms characterized by peripheral blood cytopenias and a high risk of progression to acute myeloid leukemia. MDS represent the final stage in a continuum of HSCs genetic and functional alterations and are preceded by a premalignant phase, clonal cytopenia of undetermined significance (CCUS). Dissecting the mechanisms of CCUS maintenance may uncover therapeutic targets to delay or prevent malignant transformation. Here, we demonstrate that DNMT3A and TET2 mutations, the most frequent mutations in CCUS, induce aberrant HSCs differentiation towards the myeloid lineage at the expense of erythropoiesis by upregulating IL-1{beta}-mediated inflammatory signaling and that canakinumab rescues red blood cell transfusion dependence in early-stage MDS patients with driver mutations in DNMT3A and TET2. This study illuminates the biological landscape of CCUS and offers an unprecedented opportunity for MDS intervention during its initial phase, when expected survival is prolonged.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.